2014
DOI: 10.1161/circheartfailure.114.000346
|View full text |Cite
|
Sign up to set email alerts
|

GLP-1 Agonist Therapy for Advanced Heart Failure With Reduced Ejection Fraction

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

1
20
0
1

Year Published

2016
2016
2020
2020

Publication Types

Select...
7

Relationship

2
5

Authors

Journals

citations
Cited by 41 publications
(22 citation statements)
references
References 50 publications
1
20
0
1
Order By: Relevance
“…A clinical composite may also be considered (Massie et al, 2010), although like the Finkelstein and Schoenfeld endpoint it is too ad hoc to make a general program useful, and it is easily coded. A macro was included for the unmatched win-ratio composite (derive_WR) at the web link above; see the supplementary material to Pocock et al (2012) although note the small error in the variance equation which should sum U 2 from 1 to N. The code was validated in a number of ways including reproducing power estimates for current trials such as FIGHT which uses a global rank of three outcomes (Margulies et al, 2014) and BLAST using an average Z-score for five outcomes (Felker et al, 2015), both of which used data simulations for sample size estimation. The macros have also been used to evaluate these composites (Brown, Anstrom, Felker, & Ezekowitz, 2016).…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…A clinical composite may also be considered (Massie et al, 2010), although like the Finkelstein and Schoenfeld endpoint it is too ad hoc to make a general program useful, and it is easily coded. A macro was included for the unmatched win-ratio composite (derive_WR) at the web link above; see the supplementary material to Pocock et al (2012) although note the small error in the variance equation which should sum U 2 from 1 to N. The code was validated in a number of ways including reproducing power estimates for current trials such as FIGHT which uses a global rank of three outcomes (Margulies et al, 2014) and BLAST using an average Z-score for five outcomes (Felker et al, 2015), both of which used data simulations for sample size estimation. The macros have also been used to evaluate these composites (Brown, Anstrom, Felker, & Ezekowitz, 2016).…”
Section: Resultsmentioning
confidence: 99%
“…They were used, for example, in the Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT) study which compared Liraglutide and placebo groups using a global rank composite comprising mortality, hospital readmission and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide (NTproBNP) level (Margulies et al, 2014). They were also used in the biased ligand of the angiotensin receptor study in acute heart failure (BLAST-AHF) study which used an average Z-score to BROWN & EZEKOWITZ 217 compare three dose groups and a placebo in acute patients with heart failure .…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…They were used, for example, in the Functional Impact of GLP-1 for Heart Failure Treatment (FIGHT) study which compared Liraglutide and placebo groups using a global rank composite comprising mortality, hospital readmission and time-averaged proportional change in N-terminal pro-B-type natriuretic peptide (NTproBNP) level (Margulies et al, 2014). They were also used in the biased ligand of the angiotensin receptor study in acute heart failure (BLAST-AHF) study which used an average Z-score to compare three dose groups and a placebo in acute patients with heart failure .…”
Section: Methodsmentioning
confidence: 99%
“…Patients proceed down the hierarchy until they fail on an outcome according to some criterion. A decision rule employing criteria for failure is not necessary for a global rank composite, but we follow the approach of Felker and Maisel (2010) here; 'global rank' is a generic term and various specifications could fall under this label (Califf, Harrelson-Woodlief, & Topol, 1990;Finkelstein & Schoenfeld, 1999;Lachin, 1999;Margulies et al, 2014;Pocock, Ariti, Collier, & Wang, 2012;Temkin et al, 2007). The intention is to assign every patient a rank which reflects the severity of response.…”
Section: Global Rank (%Derive_gr)mentioning
confidence: 99%